2021
DOI: 10.1177/09603271211002886
|View full text |Cite
|
Sign up to set email alerts
|

Therapeutic effects of myocardin-related transcription factor A (MRTF-A) knockout on experimental mice with nonalcoholic steatohepatitis induced by high-fat diet

Abstract: Objective: To explore the effects of myocardin-related transcription factor A (MRTF-A) knockout on mice with nonalcoholic steatohepatitis (NASH) induced by high-fat diet (HFD). Methods: Normal-fat diet (NFD) or HFD was fed to MRTF-A-knockout (MRTF-A−/−) and wild-type (WT) mice for 16 weeks. Liver histopathological status was observed using Hematoxylin and Eosin (HE) staining, Oil Red O staining, Sirius Red staining, and Immunohistochemical staining. The mRNA and protein levels in liver tissues were measured th… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

3
5
0

Year Published

2022
2022
2024
2024

Publication Types

Select...
4
2
1

Relationship

0
7

Authors

Journals

citations
Cited by 7 publications
(8 citation statements)
references
References 43 publications
3
5
0
Order By: Relevance
“…For instance, MRTF-A is upregulated in blood-circulating Mϕ associated with atherosclerotic lesions, thus a drug that supplants MRTF-A ( Velasquez et al, 2013 ; Yu-Wai-Man et al, 2017 ) may inadvertently accelerate atherosclerosis in space. Similar conclusions can be made with spaceflight diseases such as non-alcoholic fatty liver disease ( Beheshti et al, 2019 ), related to MRTF ( Zhang L. et al, 2021 ). Currently, no safe drugs have been proven for the treatment of space-induced cardiovascular disease, and evaluations of potential drugs is often contradictory ( Meerman et al, 2021 ).…”
Section: Conclusion and Recommendationssupporting
confidence: 70%
“…For instance, MRTF-A is upregulated in blood-circulating Mϕ associated with atherosclerotic lesions, thus a drug that supplants MRTF-A ( Velasquez et al, 2013 ; Yu-Wai-Man et al, 2017 ) may inadvertently accelerate atherosclerosis in space. Similar conclusions can be made with spaceflight diseases such as non-alcoholic fatty liver disease ( Beheshti et al, 2019 ), related to MRTF ( Zhang L. et al, 2021 ). Currently, no safe drugs have been proven for the treatment of space-induced cardiovascular disease, and evaluations of potential drugs is often contradictory ( Meerman et al, 2021 ).…”
Section: Conclusion and Recommendationssupporting
confidence: 70%
“…For instance, MRTF-A is upregulated in blood-circulating Mφ associated with atherosclerotic lesions, thus treatment that supplants MRTF-A may inadvertently accelerate atherosclerosis in space. Similar conclusions can be made with spaceflight diseases such non-alcoholic fatty liver disease (Beheshti et al, 2019), related to MRTF (Zhang et al, 2021). Currently, no safe drugs have been proven for the treatment of space-induced cardiovascular disease, and evaluations of potential drugs is often contradictory (Meerman et al, 2021).…”
Section: Conclusion and Recommendationssupporting
confidence: 61%
“…For instance, MRTF-A is upregulated in blood-circulating Mφ associated with atherosclerotic lesions, thus a drug that supplants MRTF-A may inadvertently accelerate atherosclerosis in space. Similar conclusions can be made with spaceflight diseases such non-alcoholic fatty liver disease (Beheshti et al, 2019), related to MRTF (Zhang et al, 2021). Currently, no safe drugs have been proven for the treatment of spaceinduced cardiovascular disease, and evaluations of potential drugs is often contradictory (Meerman et al, 2021).…”
Section: Conclusion and Recommendationssupporting
confidence: 60%